Tapinarof
- Generic Name
- Tapinarof
- Brand Names
- Vtama
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18O2
- CAS Number
- 79338-84-4
- Unique Ingredient Identifier
- 84HW7D0V04
- Background
Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in Photorhabdus luminescens, a gram-negative bacillus that lives symbiotically with the Heterorhabditis nematodes. In 1959, it was noticed that Heterorhabditis with a high amount of 3,5-dihydroxy-4-isopropylstilbene did not putrefy once dead, thus suggesting its potential anti-inflammatory activity.
Tapinarof received initial approval from the FDA in 2022.
- Indication
Tapinarof is indicated for the topical treatment of plaque psoriasis in adults.
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis)
Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis
- Conditions
- Plaque Type Psorisis
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 560
- Registration Number
- NCT06742957
- Locations
- 🇺🇸
Site 12103, College Station, Texas, United States
🇺🇸Site 12117, Houston, Texas, United States
🇺🇸Site 12109, Las Vegas, Nevada, United States
Tapinarof for Cutaneous Lupus Erythematosus
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 10
- Registration Number
- NCT06661213
- Locations
- 🇺🇸
Northwestern University Department of Dermatology, Chicago, Illinois, United States
Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 6
- Registration Number
- NCT06561321
- Locations
- 🇺🇸
Indiana University Department of Dermatology, Indianapolis, Indiana, United States
Vtama in Psoriasis Patients Being Treated With Biologics.
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Target Recruit Count
- 30
- Registration Number
- NCT06103695
- Locations
- 🇺🇸
Schweiger Derm Group, East Windsor, New Jersey, United States
Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
- Conditions
- ICD10 Code L40.9 for Psoriasis
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT05981118
- Locations
- 🇺🇸
Wake Forest University Health Sciences Department of Dermatology, Winston-Salem, North Carolina, United States
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Dermavant Sciences, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05789576
- Locations
- 🇺🇸
Dermavant Investigative Sites, Rockville, Maryland, United States
🇺🇸Dermavant Investigative Site, Arlington, Texas, United States
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Dermavant Sciences, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05680740
- Locations
- 🇺🇸
Dermavant Investigative Site, Webster, Texas, United States
Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 390
- Registration Number
- NCT05326659
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05326672
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Dermavant Sciences, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05186805
- Locations
- 🇨🇦
Dermavant Investigative Site, Calgary, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.